# Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients

> **NCT02853123** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 106 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium
- **DRUG:** Olodaterol
- **DRUG:** Tiotropium

## Key facts

- **NCT ID:** NCT02853123
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-22
- **Primary completion:** 2017-07-24
- **Final completion:** 2017-08-14
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2019-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02853123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02853123, "Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02853123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*